翻訳開始因子（eIF）抗体

幅広い翻訳開始因子抗体を販売しております。

タンパク質発現の調節

タンパク質発現の調節は細胞成長や細胞周期の進展に密接に関わっています。従って、翻訳病態生理学ではヒトの病気のメカニズムや翻訳に関わる過程が治療の ターゲットになるという認識が高まっています。mRNAの翻訳は、initiation (開始)・elongation (伸長)・termination (終結) といった段階からなります。

多くの真核生物翻訳開始因子 (eIFs) は開始段階で特異的に働きます。eIFs や 翻訳開始の最終目的は 80Sリボソームの形成とリボソームのP部位上にmRNAの開始コドン、Met-tRNAの配置をすることです。この過程は 40Sリボソームサブユニット、特異的eIFs そして eIlF2、GTP、Met-tRNA の3つからなる複合体を含む43S開始前複合体の集合から始まります。開始前複合体は48S複合体を形成するために、eIF4Fヘテロ3両体複合体を介し て mRNA の m7G cap に結合します。

この複合体は、開始コドンAUGの塩基ペアの5’ 非翻訳領域を認識します。 続いて48S複合体はバラバラに分離し、40S と 60S リボソームサブユニットに再編成し、ペプチド合成の伸長段階を指揮する 80Sリボソームを形成します。翻訳開始制御の変化はヒトの病気を発症させるメカニズムの一つとされていますので、翻訳制御を理解することで関連疾患の治 療・診療の手がかりとなります。

Detection of Human and Mouse eIF2beta/EIF2S2 by
Western Blot (h&m) and Immunoprecipitation (h).
Samples: Whole cell lysate from HeLa (5, 15 and 50 mcg forWB; 1 mg for IP,
20% of IP loaded),293T (T; 50 mcg), and mouse NIH3T3 (M; 50 mcg) cells.
Antibodies: Affi nity purified rabbit anti-eIF2beta/EIF2S2 antibody
A301-743A used for WB at 0.04 mcg/ml (A) and 1 mcg/ml (B) and used for
IP at 3 mcg/mg lysate. eIF2beta/EIF2S2 was immunoprecipitated
less effi ciently by rabbit anti-eIF2beta/EIF2S2 antibody A301-742A,
which recognizes an upstream epitope. For blotting immunoprecipitated
eIF2beta/EIF2S2 the ReliaBLOTR Reagents and Procedures
(Cat. No. WB120) were used.
Detection: Chemiluminescence with exposure times of 10 seconds (A and B).

Detection of Human EIF3S9/eIF3B by Western Blot and
Immunoprecipitation. Samples: Whole cell lysate from
HeLa (5, 15 and 50 mcg for WB; 1 mg for IP, 20% of IP
loaded) and 293T (T; 50 mcg) cells. Antibody: Affi nity purifi
ed rabbit anti-EIF3S9/eIF3B antibody A301-761A used for
WB at 0.04 mcg/ml (A) and 1 mcg/ml (B) and used for IP
at 3 mcg/mg lysate. EIF3S9/eIF3B was also immunoprecipitated
by rabbit anti-EIF3S9/eIF3B antibody A301-760A,
which recognizes an upstream epitope. For blotting immunoprecipitated
EIF3S9/eIF3B, the ReliaBLOTR Reagents
and Procedures (Cat. No. WB120) were used. Detection:
Chemiluminescence with exposure times of 10 seconds (A)
and 1 second (B).

Detection of Human eIF3X by Western Blot and Immunoprecipitation.
Samples: Whole cell lysate from HeLa (5, 15 and 50 mcg for
WB; 1 mg for IP, 20% of IP loaded) and 293T (T; 50 mcg) cells. Antibody:
Affi nity purifi ed rabbit anti-eIF3X antibody A301-764A used for
WB at 0.04 mcg/ml (A) and 1 mcg/ml (B) and used for IP at 3 mcg/
mg lysate. eIF3X was also immunoprecipitated by rabbit anti-eIF3X
antibody A301-765A, which recognizes a downstream epitope. For
blotting immunoprecipitated eIF3X, the ReliaBLOTR Reagents and
Procedures (Cat. No. WB120) were used. Detection: Chemiluminescence
with exposure times of 3 minutes (A) and 1 second (B).

Detection of Human eIF4B by Western Blot and Immunoprecipitation.
Samples: Whole cell lysate (5, 15 and 50 mcg for WB; 1 mg
for IP, 20% of IP loaded) from HeLa cells. Antibody: Affi nity purifi ed
rabbit anti-eIF4B antibody A301-767A used for WB at 0.04 mcg/ml (A)
and 1 mcg/ml (B) and used for IP at 3 mcg/mg lysate. eIF4B was also
immunoprecipitated by rabbit anti-eIF4B antibody A301-766A, which
recognizes an upstream epitope. For blotting immunoprecipitated
eIF4B, the ReliaBLOTR Reagents and Procedures (Cat. No. WB120)
were used. Detection: Chemiluminescence with exposure times of 10
seconds (A) and 3 seconds (B).

※  表示価格について